 EX-10 3 filename3.htm
Exhibit 10.7.3

THIRD AMENDMENT TO LICENSE AGREEMENT

THIS THIRD AMENDMENT TO LICENSE AGREEMENT (this Third Amendment) is made 
and entered into as of March 3, 2015 (Effective Date), by and between 
KINEX PHARMACEUTICALS, INC., a corporation organized and existing under the 
laws of the State of Delaware USA and having its principal office at 701 
Ellicott Street, Buffalo, New York 14203, United States (Kinex) and 
HANMI PHARMACEUTICAL LTD., a publicly traded company existing under the 
laws of South Korea and having its principal office at 14, 
Wiryeseong-daero,Songpa-gu, Seoul, 138-724 South Korea (Hanmi).


WITNESSTH:

WHEREAS, Hanmi and Kinex (under the name of its predecessor entity, Kinex 
Pharmaceuticals LLC) entered into a License Agreement on December 16, 2011 
for the license by Hanmi to Kinex of rights in the Hanmi Orascovery Program 
which License Agreement was previously amended by First Amendment to 
License Agreement on November 9, 2012 and Second Amendment to License 
Agreement on October 21, 2013 (the License); and

WHEREAS, Hanmi and Kinex now wish to amend the License to amend the 
definition of Territory to add India.

NOW, THEREFORE, the Parties hereby agree as follows:

1. All capitalized terms used in this Third Amendment and not defined 
herein shall have the meaning given to them in the License. Except as 
amended by this Third Amendment, the License shall continue in full force 
and effect.

2. Section 1.66 of the License is amended and restated in its entirety to 
read as follows:

Territory means the following designated countries and all countries 
within the following designated continents or economic union only: North 
America, South America, European Union, Australia, New Zealand, Russia, 
Eastern Europe, Taiwan, Hong Kong Macau, Singapore, Malaysia, Thailand, 
Vietnam, Philippines, Indonesia and India. All other countries are 
expressly excluded including, but not limited to, the Asian countries of 
Japan, Mainland China, and Korea.

3. In consideration for this Third Amendment, Kinex shall pay to Hanmi USD 
$50,000 within 45 days of the Effective Date of this Third Amendment.

IN WITNESS WHEREOF, the Parties have executed this Third Amendment as of 
the date first set forth above.
 
KINEX PHARMACEUTICALS, INC 	  	HANMI PHARMACEUTICAL LTD.
By: 	  	
[LOGO]
  	By: 	  	
[LOGO]
  	Johnson Lau, CEO 	  	 	  	Gwan-Sun Lee, President and CEO